Management of chemotherapy-associated febrile neutropenia.
about
Applying symptom appraisal models to understand sociodemographic differences in responses to possible cancer symptoms: a research agendaFactors associated with hospital length of stay among cancer patients with febrile neutropeniaA telephone survey of cancer awareness among frontline staff: informing training needsInvestigation of low 5-year relative survival for breast cancer in a London cancer network.Characteristics of patients dying within 30 days of diagnosis of breast or colorectal cancer in Scotland, 2003-2007.Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.The impact of national cancer awareness campaigns for bowel and lung cancer symptoms on sociodemographic inequalities in immediate key symptom awareness and GP attendancesChange in public awareness of symptoms and perceived barriers to seeing a doctor following Be Clear on Cancer campaigns in EnglandEstimating the potential survival gains by eliminating socioeconomic and sex inequalities in stage at diagnosis of melanoma.The impact of eliminating age inequalities in stage at diagnosis on breast cancer survival for older womenCancer-specific variation in emergency presentation by sex, age and deprivation across 27 common and rarer cancersVariation in advanced stage at diagnosis of lung and female breast cancer in an English region 2006-2009Communication about colorectal cancer screening in Britain: public preferences for an expert recommendation.What prompts help-seeking for cancer 'alarm' symptoms? A primary care based survey.Differences in cancer awareness and beliefs between Australia, Canada, Denmark, Norway, Sweden and the UK (the International Cancer Benchmarking Partnership): do they contribute to differences in cancer survival?Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric studyFulminate anaerobic bacteremia after chemotherapy for metastatic breast cancer despite the prophylactic use of GCSF.Communicating safe outpatient management of fever and neutropenia.Ethnic differences in cancer symptom awareness and barriers to seeking medical help in EnglandIndividual level covariate adjusted conditional autoregressive (indiCAR) model for disease mapping.Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors.Prevention of febrile neutropenia: use of prophylactic antibiotics.Chemotherapy for early-stage breast cancer: a brief history.Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.Recognition of cancer warning signs and anticipated delay in help-seeking in a population sample of adults in the UK.Development of a measurement tool to assess public awareness of cancer.The National Awareness and Early Diagnosis Initiative in England: assembling the evidence.Awareness of cancer symptoms and anticipated help seeking among ethnic minority groups in England.Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia.Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.Personalizing oncology treatments by predicting drug efficacy, side-effects, and improved therapy: mathematics, statistics, and their integration.Tackling antibiotic resistance in febrile neutropenia: current challenges with and recommendations for managing infections with resistant Gram-negative organisms.Febrile neutropenia: median door-to-needle time - results of an initial audit.Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy.Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model.Diagnosing cancer earlier: reviewing the evidence for improving cancer survival.The cost of the inpatient management of febrile neutropenia in cancer patients--a micro-costing study in the Irish healthcare setting.A retrospective analysis of clinical acuity markers on hospital length of stay in patients with febrile neutropenia.Management and cost analysis of cancer patients treated with G-CSF: a cohort study based on the French national healthcare insurance database.Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.
P2860
Q26830494-A66C5AF7-C043-4CBB-B13C-A33119C3F04AQ28543554-3A1DF6AD-4DC6-4E75-AE69-81BBA87AAC9FQ28740411-6ADF1EB1-58A4-4275-8DE3-4A36A34F4A30Q34250154-D3B0A7DF-0EA1-4371-9513-6F9CAB1F68A4Q34577587-94205763-FAA0-44DC-9EFA-A8076C733ABDQ34670717-D086842B-C217-4682-A180-D567A469B6B2Q35275107-926D4EDB-9571-4025-AB9E-535EA95BF2BBQ35275124-6653F50D-F38C-4D4F-8A82-2E1D8B445852Q35275296-BB90513A-E1EE-4910-AEBB-DF747EC84DC1Q35275317-3BA16C0B-DB3C-4A1F-B2A4-866575C3BC01Q35275338-70515829-6FA3-4A94-B57C-FCA47B82262EQ35832289-2CC908B3-9496-4F35-AE58-857E6E8FC1BDQ36451775-615C46D3-C69C-48DC-9F48-CAD979323EF2Q36547900-F2ED317B-19C5-4505-AF51-3A0E7D5A4EB8Q36594097-DE1CCDDA-BA02-4946-875D-50B81FF45872Q36723952-4DF3F0CB-6C3E-4F40-86D2-E70AD4C04D9AQ36856514-13C16A4B-30B8-4557-B385-81CE741494E1Q37008525-7C32463C-5BD6-4FF7-87A9-903166258BF1Q37061359-8830F9C2-DFF1-4B02-A9F4-2CEC85581B8DQ37138851-17D5050F-2329-4D44-9FCD-61EA5C72539FQ37363332-A25B9D33-AF92-4E74-8771-3994E2259219Q37363337-5EECC223-F135-4C2D-BA63-C9D7177021DAQ37363341-FC3011E0-9F56-4E86-A065-6B9B63D58D79Q37373201-2C02E080-6BAC-4BAD-B8EC-62D1680F3294Q37459613-1486E4C5-B635-4CD0-BE9E-9E6A9293897DQ37466560-767DAFFF-0369-40F9-82E9-7C9A6AEF9CC9Q37466590-F5D8D15A-8D32-4F77-AC15-8895FF038329Q37466620-6C8388CD-AFAB-487F-8131-98532BB6A43EQ37831314-7EB219D8-C09D-4EDC-8B06-77FCC279D885Q37931905-ED11E1F0-3846-49F4-93AF-F4B17143B240Q38194107-412FA084-D2BE-4AFA-AD9F-FDC11BFD2DD1Q38538705-92E09C47-7D7A-4158-9243-24D0AB7471C9Q40210717-BD0D3E44-D6A5-4D34-B2CB-AB1C6C33459CQ40346737-0D0CC7FF-9DC5-4C3A-9E6A-AF6DBFF6B890Q41882527-315B6C7F-F197-428A-98B7-E64803604ECBQ43217881-A230B384-A8E8-41A6-BD09-E5119AEE9681Q44711105-A1851288-9397-44BD-9EA0-0AA177844C31Q48173951-78CBE77D-EC0E-49AE-948D-276D79031C9EQ48606842-79FC011F-07DE-4ADC-8FBA-D84057EB22B0Q50878372-89017184-7BA6-435C-84D7-8B4AB14E1C1B
P2860
Management of chemotherapy-associated febrile neutropenia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Management of chemotherapy-associated febrile neutropenia.
@en
Management of chemotherapy-associated febrile neutropenia.
@nl
type
label
Management of chemotherapy-associated febrile neutropenia.
@en
Management of chemotherapy-associated febrile neutropenia.
@nl
prefLabel
Management of chemotherapy-associated febrile neutropenia.
@en
Management of chemotherapy-associated febrile neutropenia.
@nl
P2860
P356
P1476
Management of chemotherapy-associated febrile neutropenia.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605272
P407
P478
101 Suppl 1
P577
2009-09-01T00:00:00Z
P5875
P6179
1006886584